Literature DB >> 24628076

Intrathecal fentanyl decreases the optimal effect site concentration of propofol during spinal anaesthesia.

J S Lee1, J S Kim, M K Kim, S H Kim, J Y Kim.   

Abstract

BACKGROUND: The aim of this study was to assess the possible difference in the optimal effect site concentration of propofol for conscious sedation during spinal anaesthesia with or without intrathecal fentanyl in patients undergoing urologic surgery. The hypothesis was that intrathecal fentanyl would decrease the effect site concentration of propofol needed for conscious sedation.
METHODS: Among 43 patients, 23 patients received fentanyl 25 mcg and 20 patients received normal saline in addition to hyperbaric bupivacaine 10 mg during spinal anaesthesia. Propofol was infused at a dose determined by a modified Dixon's up-and-down method. The Cerebral State Index was recorded once target effect site concentration was reached to determine the effect of the successfulness of the conscious sedation.
RESULTS: The half maximal effective concentration (EC50) of the effect-site concentration of propofol for sedation was 1.67 ± 0.28 mcg/ml in the control group and 0.87 ± 0.15 mcg/ml in the fentanyl group (P = 0.02). The propofol dose for conscious sedation during spinal anaesthesia was decreased by 48% when intrathecal fentanyl 25 mcg was added to local anaesthetics.
CONCLUSION: The EC50 of the effect-site concentration of propofol for sedation decreased from 1.67 ± 0.28 mcg/ml to 0.87 ± 0.15 mcg/ml with the addition of 25 mcg fentanyl to a spinal anaesthetic in patients undergoing urologic surgery.
© 2014 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24628076     DOI: 10.1111/aas.12307

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  1 in total

1.  Optimal and safe standard doses of midazolam and propofol to achieve patient and doctor satisfaction with dental treatment: A prospective cohort study.

Authors:  Rikuo Masuda; Mutsumi Nonaka; Akiko Nishimura; Kinuko Gotoh; Shuichirou Oka; Takehiko Iijima
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.